This open-label, single arm study will evaluate the efficacy and safety of subcutaneously administered RoActemra/Actemra (tocilizumab), in monotherapy or in combination with methotrexate and/or other disease-modifying antirheumatic drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis. Patients will receive RoActemra/Actemra 162 mg subcutaneously weekly for at least 52 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01941940?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
